o Strong year ahead for clinical activity with Company's immunotherapies, including in combination with immune checkpoint inhibitors
o Cash and cash equivalents at December 31, 2014 of ?65.9 million
Strasbourg, France, March 24, 2015 - Transgene SA (Euronext: TNG) today announced its financial results for the fiscal year ended December 31, 2014 and provided a business update.
Clinical highlights include:
o Two Phase 3 trials in preparation for TG4010 and Pexa-Vec
o Several Phase 2 trials planned in combination with immune checkpoint inhibitors (ICIs)
o TG1050 to enter Phase 1 trial in chronic hepatitis B
More details on these developments appear later in this release.
Financial highlights include:
o Cash, cash equivalents and other financial assets at year end 2014 totaling ?65.9 million compared to ?47.9 million at year end 2013
o Net cash burn for 2014 of ?44.9 million versus ?45.0 million in 2013
o Research and development (R&D) expenses of ?49.8 million for 2014 compared to ?50.1 million for 2013
o Results for 2014 were in line with expectations
o Cash burn guidance for 2015 expected to be around ?45 million
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.69 (c)||0.75%||77 091|